Patients on lisdexamfetamine have spent years watching Adderall headlines and assuming their medication was more stable. For a while it mostly was. Then generic lisdexamfetamine started slipping, and the pattern turned out to be strange: the brand-name version kept shipping normally while the generic, the one most patients and insurance plans steer people toward, became the hard one to find. The result is an unusual problem. The medication that's in stock is often the one your insurance won't pay for at a normal price.
1. Is Vyvanse really in shortage?
You have to split brand from generic, because they behave differently.
Generic lisdexamfetamine: ASHP lists lisdexamfetamine capsules as an active shortage, with its entry revised as recently as October 28, 2026. Drugs.com's shortage list, updated in early November, shows both capsules and chewable tablets. Manufacturers named in shortage listings over the past year include Amneal, Hikma, Solco, Mallinckrodt, and Elite, with Teva reporting limited 70 mg supply. Most cite an issue with the active ingredient. Statuses change often, and some makers have moved in and out of the list.
Brand Vyvanse (Takeda): brand supply has generally stayed available, and shortage listings are about generic products. That doesn't mean every pharmacy has every strength on the shelf every day, but Takeda's supply chain hasn't reported the active-ingredient disruption several generic makers have.
Practically, the first thing to learn is whether your pharmacy is out of one generic manufacturer's product or out of lisdexamfetamine entirely. Those are different problems with different fixes.
2. Why brand works when generic doesn't
This looks backwards, since brand drugs are usually the scarce ones and generics the reliable fallback. Lisdexamfetamine lost patent exclusivity in August 2023, and roughly a dozen generic manufacturers entered at once. Prescribing shifted quickly to generic because of lower copays, while overall demand kept climbing as adult ADHD diagnosis and treatment rose. Takeda kept making brand Vyvanse on its own established line. Several new generic entrants ran into active-ingredient sourcing problems specific to their facilities and suppliers.
Because lisdexamfetamine is a Schedule II controlled substance, production of the active ingredient is federally capped by DEA quota, on top of each company's own capacity. A generic maker with a sourcing problem can't just buy more raw material elsewhere. One company can be constrained while another has no issue at all, which is why availability varies so much from store to store. It usually comes down to which manufacturer a pharmacy's wholesaler stocks.
3. Timeline
| Date | Event |
|---|---|
| Aug 2023 | Lisdexamfetamine loses patent exclusivity; roughly a dozen generic manufacturers enter the market |
| Jun 2024 | CDC issues a Health Advisory on disrupted access to prescription stimulants |
| Jul 2024 | FDA tells DEA in writing that active ingredient shortage is behind shortages of generic lisdexamfetamine |
| Sep 2024 | DEA raises the 2024 lisdexamfetamine quota in response |
| Sep 2025 | DEA raises the lisdexamfetamine quota again, from about 32.7 to 39.9 million grams |
| Nov 2025 | DEA proposes a 2026 lisdexamfetamine quota of 42,057,460 grams |
| Jan 5, 2026 | DEA finalizes the 2026 quota at 51,290,743 grams, above its proposal |
| Nov 4, 2026 | DEA raises 2026 quotas for d,l-amphetamine and d-amphetamine (for sale) in an order effective immediately |
| Nov 10, 2026 | DEA publishes its proposed 2027 quotas, including 62,832,521 grams of lisdexamfetamine; comments due December 10 |
| Nov 2026 (ongoing) | Generic lisdexamfetamine capsules and chewable tablets remain on shortage lists; brand Vyvanse generally available |
4. Which generic will your pharmacy have?
"The lisdexamfetamine shortage" is really a patchwork of individual manufacturer statuses, and those statuses shift month to month. A manufacturer listed as short in one snapshot may be listed as available in the next. Rather than trusting a static table, use these steps:
- Ask your pharmacist which manufacturer they currently stock and whether they can order a different one.
- Check ASHP's lisdexamfetamine entry for the latest manufacturer-by-manufacturer status.
- Call independent pharmacies as well as chains. They often use different wholesalers and stock different generic makers.
- Ask about a different strength combination if your prescriber agrees (for example, two capsules adding up to your dose), since individual strengths can go in and out of stock independently.
Practical tip: a pharmacy that's out of one maker's generic may still be able to order another's. Calling a second or third pharmacy often turns up a different manufacturer's product.
5. The DEA quota: what 62.8 million grams means
Because lisdexamfetamine is Schedule II, the DEA sets an annual aggregate production quota (APQ) that caps how much of the active ingredient all manufacturers combined may produce in the U.S. that year.
On November 10, 2026, the DEA published proposed 2027 quotas, including 62,832,521 grams of lisdexamfetamine. That compares with 51,290,743 grams finalized for 2026 and a 2026 proposal of 42,057,460 grams. Comments are due December 10, 2026, and the final 2027 numbers come only after the DEA reviews them. In the notice, the DEA says FDA expects domestic stimulant use to rise about 3.9% in 2027 and cites shortage concerns tied to telemedicine growth, supply chain problems, and manufacturing and quality issues.
A higher quota raises the legal ceiling. It doesn't fix a specific company's raw-material contract, packaging capacity, or quality-control backlog. That's the same gap that kept the Adderall shortage going after earlier quota increases, and it's why several lisdexamfetamine makers still report shortage status well after the ceiling went up. A significant share of the quota also supports exports, so the increase for U.S. patients is smaller than the headline number.
6. When will the shortage end?
No agency has published an end date for the generic shortage, and treating any projection as a plan is risky, since timelines for this drug class have slipped repeatedly since 2022. What would actually resolve it is each affected manufacturer fixing its own ingredient supply, independent of the quota. Some may recover in weeks; others haven't published a recovery estimate. Brand Vyvanse's steady supply doesn't speed generic recovery, because the operations are separate.
The realistic outlook is continued store-by-store inconsistency for generic lisdexamfetamine, with brand the more dependable option if your plan and budget allow. If your prescription depends on a manufacturer in shortage, ask your prescriber whether writing it so any manufacturer's product can be dispensed helps your pharmacist source it faster.
7. The insurance problem: why your plan won't cover brand
Most commercial and Medicare Part D formularies put brand-name drugs in a higher tier, or exclude them, once a generic exists. That rule turns on whether a generic exists nationally, not on whether it's in stock near you. A plan can be technically right that generic lisdexamfetamine is available while several pharmacies near you have none.
The practical result: a patient whose pharmacy is out of every generic may still face a high brand-tier copay or a denial, because as far as the insurer's system is concerned, nothing has changed.
How the workaround usually works
- Shortage documentation from your prescriber. Some plans will process a temporary exception if your prescriber documents that generic was unavailable at your pharmacy or several nearby ones on specific dates.
- Formulary exception request. A formal request that the plan cover a non-preferred or excluded drug at a lower tier for a documented access or clinical reason.
- Prior authorization for brand. Some plans route brand requests through standard prior authorization. Ask which process yours uses.
- Appeal if denied. A denial isn't final, and a dated record of the pharmacies you checked strengthens an appeal.
Our prior authorization and appeal guide walks through the process for major pharmacy benefit managers.
Open enrollment matters here. If you're choosing a 2027 plan, check how it treats lisdexamfetamine and brand Vyvanse: tiers, prior authorization, and quantity limits. Medicare open enrollment ends December 7. For HealthCare.gov plans, choose by December 15 for January 1 coverage; enrollment runs through January 15. Our guide to picking a Marketplace plan that covers your prescriptions shows how to check a drug against a plan.
8. Brand vs generic Vyvanse
| Factor | Brand Vyvanse (Takeda) | Generic lisdexamfetamine |
|---|---|---|
| Availability | Generally in stock | Inconsistent by manufacturer |
| Active ingredient | Lisdexamfetamine dimesylate | Same (bioequivalent) |
| Typical cash price | Higher, often several hundred dollars | Lower, and often much lower with a discount card |
| Typical insurance tier | Higher tier or excluded once generic exists | Usually preferred tier |
| Manufacturer support | Help at Hand PAP; copay card terms vary, so confirm | No manufacturer PAP; use discount cards |
| Best when | Generic is out everywhere and you can get an exception approved | Your usual manufacturer's product is in stock |
Sticking with generic
- Lower tier, and usually the cheaper cash option when in stock
- A different manufacturer may have supply when your usual one doesn't
- No exception paperwork if your plan already covers it
Switching to brand
- May need prescriber and insurer paperwork to avoid a high cost
- Cash price is much higher without a coupon or approved exception
- Approval at generic pricing isn't guaranteed
9. If your pharmacy is out
Ask which manufacturer they're out of
"Out of lisdexamfetamine" and "out of the one manufacturer we usually carry" are different problems. Ask whether another maker's product can be ordered.
Call two or three other pharmacies first
Independents and different chains often stock different manufacturers. This also gives you a clearer picture and a record for any later insurer request.
Ask about a partial fill
Federal rules generally allow partial fills of Schedule II prescriptions as long as the total across fills doesn't exceed the amount prescribed. State rules and pharmacy policies also apply.
If no generic is available nearby, ask your prescriber about brand
Ask the office to document which pharmacies you checked and on what dates. That record is often what an exception or appeal needs.
Confirm coverage before you fill brand
Call your insurer or check your plan portal first, so you aren't surprised by a denial or a high cash price.
Plan ahead for December 31 if you use telehealth
DEA's temporary telemedicine flexibilities for controlled substances run through December 31, 2026. Ask your prescriber how your next prescription will be handled in 2027, and don't wait for your last fill to raise it.
Don't stop abruptly while you sort this out
CDC's 2024 advisory flagged the risks of disrupted stimulant access, including fatigue, mood changes, and turning to unregulated substitutes. Talk to your prescriber about a short bridge plan rather than going without.
10. Assistance and savings options
- Takeda Help at Hand: Takeda's patient assistance program for people who are uninsured or underinsured. Eligibility and covered products are set by Takeda, so confirm current criteria before applying.
- Manufacturer copay card: availability has shifted since generic entry. See our Vyvanse savings card guide.
- Cash pricing: compare prices in our Vyvanse cost without insurance guide.
- Discount cards for generic: free cards like Inside Rx, compared in our Inside Rx vs SingleCare breakdown, can lower the generic's cash price a lot. Compare against your insurance copay, since cash purchases may not count toward your deductible.
- Broader searches: see programs that help pay for prescriptions and how patient assistance programs work.
- Medicare enrollees: read about Part D changes and whether Medicare patients can use patient assistance programs.
- Extra Help (Low-Income Subsidy): can substantially lower what you pay for covered Part D drugs if your income and assets qualify.
11. Eligibility and applications
| Program | Who it's for | Covers |
|---|---|---|
| Takeda Help at Hand | Uninsured or underinsured patients prescribed a Takeda medication; income proof required | Eligible Takeda brand products only |
| Discount cards | Anyone; no income requirement | Most generics, including lisdexamfetamine |
| Medicare Extra Help | Part D enrollees with limited income and resources | Covered Part D drugs on formulary |
| NeedyMeds / BenefitsCheckUp | Anyone searching across many programs | Aggregates assistance and state or local resources |
| State pharmacy assistance | State residents who meet state rules | Varies by state |
How applications generally work
- Help at Hand: get the application from Takeda's site, include proof of income such as a recent tax return, and have your prescriber complete the clinical section. Takeda describes review as taking a few business days once complete, and approvals typically last up to a year before renewal.
- Extra Help: apply through Social Security or your state Medicaid office with income and resource details for you and any spouse.
- Discount cards: no application; use the card or app at checkout.
Medicare's Extra Help limits are updated yearly by CMS at Medicare.gov. Manufacturer thresholds aren't standardized, so confirm on each program's site.
12. Common mistakes that delay access
- Assuming your insurer will switch you to brand without documentation.
- Only calling pharmacies in one chain.
- Waiting until the day you run out. Exceptions and applications take time, so start a week or more ahead.
- Assuming an old coupon still applies.
- Trying to stockpile a 90-day supply, which most plans and pharmacies won't allow for Schedule II drugs.
- Not recording which pharmacies you checked and when.
- Ignoring the December 31 telehealth change if that's how you're prescribed.
13. What should you do right now?
Ask the office to document the pharmacies and dates you checked, then contact your insurer about a formulary exception or prior authorization before filling brand. Don't ration doses or stop abruptly in the meantime.
Related: Adderall Shortage 2026: When Will It End, XR Status & What to Do Now. It covers the parallel Adderall shortage, including the DEA's November quota increases.
Primary sources referenced
- Federal Register, Nov 10, 2026: DEA proposed 2027 aggregate production quotas and 2026 quota adjustments
- Federal Register, Jan 5, 2026: Established 2026 aggregate production quotas
- ASHP Drug Shortages: Lisdexamfetamine Dimesylate Capsules
- Drugs.com Current Drug Shortages
- FDA Drug Shortages Database
- CDC Health Alert Network advisories
- Takeda Help at Hand
- Medicare.gov · NeedyMeds · BenefitsCheckUp
